According to the national medical insurance bureau released on July 30? Order 1? "Interim Measures for the Administration of Medication in Basic Medical Insurance", China has established and improved the dynamic adjustment mechanism of medical insurance catalogue, which is adjusted once a year in principle. The Interim Measures shall come into force as of September 6, 2020.
According to the exposure draft, seven types of drugs outside the medical insurance catalogue can be included in the scope of drugs added to the medical insurance catalogue in 2020, including drugs for treating respiratory diseases related to COVID-19; Drugs listed in the National Catalogue of Essential Drugs (version 20 18); Drugs that are listed in the list of overseas new drugs urgently needed in clinic, encouraged to imitate drugs or encouraged to develop and declare the list of children's drugs, and approved to be listed in National Medical Products Administration before 20 19 12 3 1; The second batch of drugs organized by the state for centralized drug procurement.
It is worth noting that the scope of drugs added this time also includes drugs (including new active ingredients and new dosage forms) approved for marketing in National Medical Products Administration according to the new drug registration and declaration procedures from 20 15 to 20 19 to 12. Experts pointed out that this means that more new drugs and good drugs are expected to be included in medical insurance, and the people's access to quality medical services will be accelerated.
In addition, according to the exposure draft, compared with other drugs in the same treatment field, drugs with significantly higher price/cost and more funds in recent years are planned to be included in the scope of medical insurance catalogue adjustment in 2020.
Since the outbreak of new crown pneumonia, the national medical insurance bureau has been issuing? Two guarantees? Policy, all confirmed and suspected patients are treated first and then settled. As of July 19, there were135,500 medical insurance settlements for confirmed and suspected patients in COVID-19, involving medical expenses184.7 billion yuan and medical insurance payment12.32 million yuan, with the payment ratio reaching 67%.
Experts pointed out that the medical insurance catalogue adjustment plan will bring the drugs related to new coronary pneumonia into a new scope, which will provide important support for the normalization of epidemic prevention and control in COVID-19.